AstraZeneca’s Farxiga is already ahead of rivals in the SGLT2 inhibitor field in heart failure, and now looks set to repeat that success in renal disease after reporting stella
The FDA’s approval of AstraZeneca’s SGLT2 inhibitor Farxiga in heart failure was a first for the class, but Boehringer Ingelheim and Eli Lilly are closing the gap with a positi
Lilly and Boehringer Ingelheim will now be able to promote their drug Jardiance in the US as a way for diabetes patients to reduce their risk of having a heart attack or stroke.
New drugs from Eli Lilly have produced a strong showing in the first quarter, in what could be a key year for a company still recovering from patent expiry of its former blockbuster antidep